The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMbrave150: Exploratory analysis to examine the association between bevacizumab (bev) ever being skipped and bev never being skipped in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bev in a global phase 3 study.
 
Masatoshi Kudo
Honoraria - Bayer; Chugai/Roche; Eisai; Lilly Japan; Takeda
Research Funding - Abbvie (Inst); Chugai/Roche; EA Pharma (Inst); Eisai (Inst); GE Healthcare; Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Kaoru Tsuchiya
Consulting or Advisory Role - Chugai Pharma; Eisai
Speakers' Bureau - Chugai Pharma; Eisai; Lilly Japan; Takeda
 
Yu Yun Shao
Honoraria - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; Ipsen; Lilly; Merck; Ono Pharmaceutical; Roche
Speakers' Bureau - AstraZeneca; AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; Lilly; Merck; Merck Serono; Ono Pharmaceutical; Roche
Research Funding - AstraZeneca
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer
 
Peter R. Galle
Honoraria - Adaptimmune; AstraZeneca/MedImmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Guerbet; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Boston Scientific; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Bayer; Pierre Fabre; Roche/Genentech; TERUMO
Consulting or Advisory Role - Amgen; AstraZeneca; Basilea; Bayer; Daiichi Sankyo/Astra Zeneca; GlaxoSmithKline; HalioDx; Ipsen; Lilly; Merck Serono; MSD; Novartis; Pierre Fabre; Rafael Pharmaceuticals; Roche; Servier; Sotio; Zymeworks
Speakers' Bureau - Amgen; AstraZeneca; Bayer; GlaxoSmithKline; HalioDx; Lilly; Merck KGaA; MSD; Pierre Fabre; Roche; SERVIER
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Merck Serono; Pierre Fabre; Roche; SERVIER
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Yakuhin; Eisai; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer Schering Pharma; BeiGene; Bristol-Myers Squibb; Eisai; Genentech/Roche; Ipsen; IQVIA; MSD; Ono Pharmaceutical; Roche
 
Tatsuya Yamashita
Speakers' Bureau - Bayer; Chugai Pharma; Eisai; Lilly; Sumitomo Dainippon Pharma Oncology; Takeda
 
Hironori Koga
No Relationships to Disclose
 
Kenichi Aoki
Employment - Chugai/Roche
 
Kyoko Yamada
Employment - Chugai Pharma
 
Takashi Asakawa
Employment - Chugai Pharma
 
Yuki Nakagawa
Employment - Chugai Pharma
Stock and Other Ownership Interests - Chugai Pharma
 
Masafumi Ikeda
Honoraria - Abbott Laboratories; Abbvie; AstraZeneca; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; EA Pharma; Eisai; Fujifilm; Incyte; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; EMD Serono; GlaxoSmithKline; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; SERVIER; Takeda
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Syneos Health (Inst)